Field Trial of Maternal Influenza Immunization in Asia (Mothers'Gift)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01034254|
Recruitment Status : Unknown
Verified March 2016 by Children's Hospital Medical Center, Cincinnati.
Recruitment status was: Active, not recruiting
First Posted : December 17, 2009
Last Update Posted : March 7, 2016
|Condition or disease||Intervention/treatment||Phase|
|Influenza Human||Biological: influenza vaccine Biological: saline placebo||Phase 3|
This is a community-based, placebo-controlled, individually randomized trial in trial among women who are or who become pregnant in 9 Village Development Committees in Sarlahi District, Nepal. The study population for this trial will include all women who are identified as pregnant with gestational age between 17 and 34 weeks gestation during a 12-month period in 9 Village Development Committees (VDC) of Sarlahi District, Nepal. The 9 VDCs include: Dhungre Khola, Karmaiya, Hariaun, Ghurkauli, Sasapur, Netraganj, Lalbandi, Jabdi, and Raniganj.
The vaccine that will be given will be the most current vaccine at the time of subject enrollment. That is, for women enrolled after October in either study cohort, the vaccine will be switched to the newly available vaccine for that year.
The control group will be placebo (saline injection). The justification for the use of a placebo injection in this trial is as follows: There is only one trial (Bangladesh) that demonstrates efficacy of influenza vaccination in pregnancy on perinatal outcomes and respiratory morbidity in early infancy. One of the issues with that study is that it was not placebo controlled. The "control" in that study was adult pneumococcal vaccine. It could be that the Bangladesh study underestimated the impact of influenza vaccine because the mothers and infants receive some indirect protection from the pneumococcal vaccine. In addition, influenza vaccine is not part of national policy or recommendations in Nepal at the current time and Ministry of Health officials are very interested in the results of our study as they consider their immunization program expansion over the next few years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Field Trial of Maternal Influenza Immunization in Asia|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
Experimental: influenza vaccine
Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
Biological: influenza vaccine
Pregnant women will receive FDA approved influenza vaccine.
Other Name: "VAXIGRIP®
Placebo Comparator: saline placebo
Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
Biological: saline placebo
Vaccination of pregnant women with saline placebo.
Other Name: saline
- Field Trial of Maternal Influenza Immunization [ Time Frame: 2 annual recruitment cycles coinciding with flu seasons ]
To compare, in women randomized to receive either influenza vaccine or control during pregnancy and their infants (through 6 months of age)
a) the incidence of influenza-like illness or lab-confirmed influenza episodes b) the distribution of causes of febrile illness and the incidence of clinic visits and hospitalizations c) the incidence of low birth weight, the distribution of birth weight and gestational age and the growth of infants.
- Substudy #1: Transplacental Transfer of Influenza Antibody from Mother to Infant [ Time Frame: 2 annual recruitment cycles ]
- To estimate the efficacy of maternal vaccination for producing an immune response in the mother and for passive antibody transfer to the infant.
- To determine if timing of vaccination during pregnancy or other maternal factors such as nutritional status are related to level of antibody transfer to the infant.
- To compare neutralizing antibody concentrations in breastmilk of women randomized to receive either influenza vaccine or control during pregnancy.
- Substudy #2: Indirect Protection of Maternal Influenza Vaccination on Family Members [ Time Frame: 2 annual recruiting cycles ]Specific Aim: To compare the indirect protection of influenza vaccine on influenza-like and influenza-specific febrile illness rates in families of study women.
- Substudy #3: Hepatitis E Infection in Pregnancy [ Time Frame: 2 annual recruiting cycles ]
- To estimate the prevalence of anti-hepatitis E immunoglobulin G in women of reproductive age in rural Nepal.
To estimate the incidence of hepatitis E infection (anti-hepatitis E seroconversion) during pregnancy in rural Nepal.
- To estimate the disease to infection ratio among women who seroconvert.
- To evaluate biochemical correlates of clinical disease among women who seroconvert.
- To describe pregnancy outcomes (miscarriage, stillbirth, neonatal mortality, maternal mortality) associated with women identified with incident infection or acute hepatitis E disease.
- Pertussis In Infants [ Time Frame: 2 annual rucruiting cycles ]Estimate the incidence of pertussis in infants under 6 months of age and the protection afforded by maternal antibody transfer to infants.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01034254
|Institute of Medicine, Tribhuvan Univerisity|
|Principal Investigator:||Mark C Steinhoff, MD||Children's Hospital Medical Center, Cincinnati|